TY - JOUR
T1 - G72 gene is associated with susceptibility to methamphetamine psychosis
AU - Kotaka, Tatsuya
AU - Ujike, Hiroshi
AU - Okahisa, Yuko
AU - Takaki, Manabu
AU - Nakata, Kenji
AU - Kodama, Masafumi
AU - Inada, Toshiya
AU - Yamada, Mitsuhiko
AU - Uchimura, Naohisa
AU - Iwata, Nakao
AU - Sora, Ichiro
AU - Iyo, Masaomi
AU - Ozaki, Norio
AU - Kuroda, Shigetoshi
N1 - Funding Information:
We thank the Zikei Institute of Psychiatry (Okayama, Japan), the Ministry of Health, Labor, Welfare of Japan and the Ministry of Education, Culture, Sports, Science and Technology, and the Mitsubishi Pharma Research Foundation.
PY - 2009/8/31
Y1 - 2009/8/31
N2 - Methamphetamine psychosis is considered as one of the pharmacological models of schizophrenia, and a hyperdopaminergic one. However, many lines of experimental evidence indicate that glutamatergic signaling is also involved in development of methamphetamine psychosis. Several genes related to glutamate function, e.g. the DTNBP1, G72, and GRM3 genes, were shown to be associated with schizophrenia susceptibility. Recently, we found significant association of the DTNBP1 gene with methamphetamine psychosis. This finding prompted us to examine the G72 gene encoding the d-amino acid oxidase activator (DAOA), which metabolizes d-serine, an NMDA co-agonist, in methamphetamine psychosis. Six SNPs of the G72 gene, which previously showed significant association with schizophrenia, were analyzed in 209 patients with methamphetamine psychosis and 291 age- and sex-matched normal controls. One SNP of M22 (rs778293) showed a significant association with methamphetamine psychosis (genotype: p = 0.00016, allele: p = 0.0015). Two haplotypes G-A of M12 (rs3916965)-M15 (rs2391191) (p = 0.00024) and T-T of M23 (rs947267)-M24 (rs1421292) (p = 0.00085) also showed associations with methamphetamine psychosis. The present findings suggest that the G72 gene may contribute to a predisposition to not only schizophrenia but also to methamphetamine psychosis.
AB - Methamphetamine psychosis is considered as one of the pharmacological models of schizophrenia, and a hyperdopaminergic one. However, many lines of experimental evidence indicate that glutamatergic signaling is also involved in development of methamphetamine psychosis. Several genes related to glutamate function, e.g. the DTNBP1, G72, and GRM3 genes, were shown to be associated with schizophrenia susceptibility. Recently, we found significant association of the DTNBP1 gene with methamphetamine psychosis. This finding prompted us to examine the G72 gene encoding the d-amino acid oxidase activator (DAOA), which metabolizes d-serine, an NMDA co-agonist, in methamphetamine psychosis. Six SNPs of the G72 gene, which previously showed significant association with schizophrenia, were analyzed in 209 patients with methamphetamine psychosis and 291 age- and sex-matched normal controls. One SNP of M22 (rs778293) showed a significant association with methamphetamine psychosis (genotype: p = 0.00016, allele: p = 0.0015). Two haplotypes G-A of M12 (rs3916965)-M15 (rs2391191) (p = 0.00024) and T-T of M23 (rs947267)-M24 (rs1421292) (p = 0.00085) also showed associations with methamphetamine psychosis. The present findings suggest that the G72 gene may contribute to a predisposition to not only schizophrenia but also to methamphetamine psychosis.
UR - http://www.scopus.com/inward/record.url?scp=67651098835&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67651098835&partnerID=8YFLogxK
U2 - 10.1016/j.pnpbp.2009.05.017
DO - 10.1016/j.pnpbp.2009.05.017
M3 - Article
C2 - 19482054
AN - SCOPUS:67651098835
SN - 0278-5846
VL - 33
SP - 1046
EP - 1049
JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry
JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry
IS - 6
ER -